PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT8213120

| SUBMISSION TYPE: | NEW ASSIGNMENT | | |
|-----------------------|------------------------------|--|--|
| NATURE OF CONVEYANCE: | RELEASE OF SECURITY INTEREST | | |

CONVEYING PARTY DATA

| Name | Execution Date |
|---|----------------|
| ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP | 10/10/2023 |

RECEIVING PARTY DATA

| Name: | PALETTE LIFE SCIENCES, INC. | |
|--------------------------|--|--|
| Street Address: | 180 STATE STREET, STE 201 | |
| City: | SOUTHLAKE | |
| State/Country: | TEXAS | |
| Postal Code: | 76092 | |
| | | |
| Name: | PALETTE LIFE SCIENCES AB | |
| Name: Street Address: | PALETTE LIFE SCIENCES AB 180 STATE STREET, STE 201 | |
| | | |
| Street Address: | 180 STATE STREET, STE 201 | |

PROPERTY NUMBERS Total: 10

| Property Type | Number |
|---------------------|----------|
| Application Number: | 62843267 |
| Application Number: | 17522674 |
| Application Number: | 61325418 |
| Patent Number: | 8828437 |
| Patent Number: | 8834927 |
| Patent Number: | 9254263 |
| Patent Number: | D685910 |
| Application Number: | 16593941 |
| Application Number: | 17941713 |
| Application Number: | 60560258 |

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: akwon@cov.com

PATENT REEL: 065172 FRAME: 0138

508165939

Correspondent Name: COVINGTON & BURLING LLP

Address Line 1: ONE CITY CENTER, 850 TENTH ST NW

Address Line 2: ATTN: PATENT DOCKET

Address Line 4: WASHINGTON, D.C. 20001

| ATTORNEY DOCKET NUMBER: | 034550.00107 |
|-------------------------|------------------|
| NAME OF SUBMITTER: | ASHLEY M. KWON |
| SIGNATURE: | /Ashley M. Kwon/ |
| DATE SIGNED: | 10/10/2023 |

Total Attachments: 5

source=Palette - Release of Patent Security Interest [Execution Version]#page1.tif source=Palette - Release of Patent Security Interest [Execution Version]#page2.tif source=Palette - Release of Patent Security Interest [Execution Version]#page3.tif source=Palette - Release of Patent Security Interest [Execution Version]#page4.tif source=Palette - Release of Patent Security Interest [Execution Version]#page5.tif

RELEASE OF SECURITY INTEREST IN PATENTS

This RELEASE OF SECURITY INTEREST IN PATENTS (this "Release") is made and effective as of October 10, 2023 and granted by ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, a Delaware limited partnership (together with its Affiliates, successors, transferees and assignees, the "Lender"), in favor of PALETTE LIFE SCIENCES, INC., a Delaware corporation, and PALETTE LIFE SCIENCES AB, a private limited company organized in Sweden with reg. no. 556785-1158 (each a "Grantor" and, collectively, the "Grantors").

WHEREAS, pursuant to that certain Credit Agreement, dated as of March 20, 2023 (as amended, supplemented or otherwise modified from time to time, the "Credit Agreement"), by and among the Grantors and the Lender, the Grantors executed and delivered to the Lender (i) that certain Pledge and Security Agreement, dated as of March 20, 2023 (as amended, supplemented or otherwise modified from time to time, the "Pledge & Security Agreement"), by and among the Grantors, its Affiliates from time to time party thereto and the Lender and (ii) that certain Patent Security Agreement, dated as of March 20, 2023 (the "Patent Security Agreement" and together with the Pledge & Security Agreement, the "Security Agreements"), by the Grantors in favor of the Lender;

WHEREAS, pursuant to the Security Agreements, each Grantor pledged and granted to the Lender for its benefit a security interest in and to all of the right, title and interest of such Grantor in, to and under the Patent Collateral (as defined in the Patent Security Agreement);

WHEREAS, the Patent Security Agreement was recorded with the United States Patent and Trademark Office at Reel 063044, Frame 0044 on March 21, 2023, with a corrective assignment recorded at Reel 064002, Frame 0531 on April 18, 2023; and

WHEREAS, the Lender wishes to provide a document evidencing the release, relinquishment and discharge of its security interest in the Patent Collateral.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Lender hereby states as follows:

1. Release of Security Interest. The Lender, on behalf of itself and its successors, legal representatives and assigns, hereby terminates the Patent Security Agreement and terminates, releases and discharges any and all security interests that it has pursuant to the Patent Security Agreement in any and all right, title and interest of the Grantors, and reassigns to the Grantors any and all right, title and interest that it may have, in, to and under the Patent Collateral (including the patents and patent licenses listed on **Schedule 1** hereto).

- 2. <u>Authorization</u>. The Lender hereby authorizes and requests the United States Patent and Trademark Office and any other applicable government officer to record this Release.
- 3. <u>Further Assurances</u>. The Lender agrees, at the Grantors' expense, to take all further actions, and provide to the Grantors and their successors, assigns and legal representatives all such cooperation and assistance, including, without limitation, the execution and delivery of any and all further documents or other instruments, as such Grantor and its successors, assigns and legal representatives may reasonably request in order to confirm, effectuate or record this Release.
- 3. <u>Execution in Counterparts</u>. This Release may be executed in any number of counterparts and by the different parties hereto on separate counterparts, each of which when so executed and delivered shall be an original, but all of which counterparts taken together shall be deemed to constitute one and the same instrument. Telecopied signatures hereto shall be of the same force and effect as an original of a manually signed copy.
- 4. Governing Law. THIS RELEASE AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE UNITED STATES AND THE STATE OF NEW YORK WITHOUT REFERENCE TO ANY CHOICE OR CONFLICT OF LAW DOCTRINE THAT WOULD RESULT IN THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION.

[Signature Page Follows]

2

IN WITNESS WHEREOF, the Lender has caused this Release to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP

as the Lender

By OrbiMed ROF IV LLC, its General Partner

By OrbiMed Advisors LLC, its Managing Member

Docusigned by:

By: Matthew Kizzo

Name: Matthew Rizzo

Title: Member

REEL: 065172 FRAME: 0142

Schedule 1

Patents and Patent Licenses

Item A. Patents

| Grantor | Country | Application No. | Filing Date | Patent No. | Issue Date | Title |
|-----------------------------------|---------|-----------------|-------------|--------------|------------|--|
| Palette Life Sciences, Inc. | US | 62/843,267 | 05/03/2019 | - | - | IMPROVED TISSUE SPACERS |
| Palette Life Sciences, Inc. | US | 17/522,674 | 05/03/2019 | - | - | IMPROVED TISSUE SPACERS |
| Palette Life Sciences AB | US | 61/325,418 | 04/19/2010 | - | - | PHN 1-1 US Prov |
| Palette Life Sciences AB | US | - | - | 8,828,437 B2 | 09/09/2014 | Thermogelling anaesthetic compositions |
| Palette Life Sciences AB | US | - | - | 8,834,927 B2 | 09/16/2014 | Thermogelling anaesthetic compositions |
| Palette Life Sciences AB | US | - | - | 9,254,263 B2 | 02/09/2016 | Thermogelling anaesthetic compositions |
| Palette Life Sciences AB | US | 29/422,499 | 05/22/2012 | D685,910 | 07/09/2013 | APPLICATOR |

Item B. Patent Licenses

| Country | Licensor / Applicant | Licensee | Application No. | Filing Date | Subject Matter |
|-----------|-------------------------|-----------------------------|-----------------|-------------|--------------------------|
| <u>US</u> | Nestle Skin | Palette Life Sciences AB | 16/593,941 | 10/04/2019 | METHOD OF SOFT TISSUE |

| | Health | | | | AUGMENTATION |
|-----------|---------------------|-----------------------------|------------|------------|--|
| <u>US</u> | Galderma Holding | Palette Life Sciences AB | 17/941,713 | 09/09/2022 | METHOD OF SOFT TISSUE AUGMENTATION |
| <u>US</u> | Q-Med AB | Palette Life Sciences AB | 60/560,258 | 04/08/2004 | METHOD OF SOFT TISSUE AUGMENTATION |

RECORDED: 10/10/2023